Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England

Industry Has Mixed Response To “Largest And Most Comprehensive Review”

Executive Summary

Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.

You may also be interested in...

RWE Accepted As ‘Primary Evidence’ In 20% Of NICE Appraisals Over Past Year

NICE, the health technology assessment body for England and Wales, says it has seen “good uptake” of its new evaluation methods manual and real-world evidence framework, both introduced last year.

Sanofi’s Orbis-Approved GVHD Drug Rezurock Rejected For English Funding

NICE has provisionally turned down three products for funding under the National Health Service in England: Sanofi’s Rezurock for chronic graft-versus-host disease, Sobi’s lymphoma drug Zynlonta, and AstraZeneca/Daiichi Sankyo’s Enhertu for the new indication of HER2-low breast cancer.

England’s NICE Consults On Health Technology Evaluations Guide Incorporating Proportionate Approach

NICE, the health technology appraisal body for England and Wales, is asking for views on amendments to its health technology evaluations manual to incorporate its new proportionate approach to appraisals.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts